Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Short-term Investments (2023 - 2025)

Beta Bionics' Short-term Investments history spans 3 years, with the latest figure at $100000.0 for Q4 2025.

  • For Q4 2025, Short-term Investments fell 99.86% year-over-year to $100000.0; the TTM value through Dec 2025 reached $100000.0, down 99.86%, while the annual FY2025 figure was $100000.0, 99.86% down from the prior year.
  • Short-term Investments for Q4 2025 was $100000.0 at Beta Bionics, down from $190.2 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $214.6 million in Q2 2025 and bottomed at $100000.0 in Q4 2025.
  • The 3-year median for Short-term Investments is $131.1 million (2024), against an average of $122.9 million.
  • The largest annual shift saw Short-term Investments increased 4.22% in 2024 before it crashed 99.86% in 2025.
  • A 3-year view of Short-term Investments shows it stood at $70.2 million in 2023, then rose by 4.22% to $73.1 million in 2024, then plummeted by 99.86% to $100000.0 in 2025.
  • Per Business Quant, the three most recent readings for BBNX's Short-term Investments are $100000.0 (Q4 2025), $190.2 million (Q3 2025), and $214.6 million (Q2 2025).